J. Ireson

Exploring invisibility and epistemic injustice in Long Covid—A citizen science qualitative analysis of patient stories from an online Covid community

Elad Richardson, J. Ireson, Amy Taylor, 2022, Health expectations : an international journal of public participation in health care and health policy.

M‐EA (methotrexate, etoposide, dactinomycin) and EMA‐CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first‐line treatment of high‐risk gestational trophoblastic neoplasia

R. Coleman, J. Tidy, B. Hancock, 2020, International journal of cancer.

Experiences of Women With Gestational Trophoblastic Neoplasia Treated With High-Dose Chemotherapy and Stem Cell Transplantation: A Qualitative Study.

M. Seckl, B. Hancock, C. Warnock, 2017, Oncology nursing forum.

Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.

R. Coleman, J. Tidy, B. Hancock, 2016, Gynecologic oncology.

Systematic review of health-related quality of life and patient-reported outcome measures in gestational trophoblastic disease: a parallel synthesis approach.

Georgina L Jones, J. Tidy, S. Radley, 2018, The Lancet. Oncology.

Leptomeningeal disease as a presenting feature of gestational trophoblastic neoplasia: A review and recommendations for management.

J. Tidy, C. Romanowski, M. Winter, 2023, Gynecologic oncology.

Systematic review of health-related quality of life and patient-reported outcome measures in gestational trophoblastic disease: a parallel synthesis approach.

J. Tidy, M. Winter, J. Ireson, 2018, The Lancet. Oncology.